During the last session, Verve Therapeutics Inc (NASDAQ:VERV)’s traded shares were 4.71 million, with the beta value of the company hitting 1.76. At the end of the trading day, the stock’s price was $13.81, reflecting an intraday gain of 1.54% or $0.21. The 52-week high for the VERV share is $21.42, that puts it down -55.1 from that peak though still a striking 40.48% gain since the share price plummeted to a 52-week low of $8.22. The company’s market capitalization is $1.08B, and the average intraday trading volume over the past 10 days was 1.09 million shares, and the average trade volume was 1.09 million shares over the past three months.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Verve Therapeutics Inc (VERV) registered a 1.54% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.54% in intraday trading to $13.81, hitting a weekly high. The stock’s 5-day price performance is -7.69%, and it has moved by 8.31% in 30 days. Based on these gigs, the overall price performance for the year is -19.00%. The short interest in Verve Therapeutics Inc (NASDAQ:VERV) is 12.52 million shares and it means that shorts have 10.8 day(s) to cover.
Verve Therapeutics Inc (VERV) estimates and forecasts
Statistics show that Verve Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Verve Therapeutics Inc (VERV) shares have gone up 6.97% during the last six months, with a year-to-date growth rate less than the industry average at 2.56% against 11.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 13.10% this quarter and then jump 14.90% in the quarter after that. In the rating firms’ projections, revenue will increase 23.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $2.53 million as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $2.97 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $1.4 million and $2.09 million respectively. In this case, analysts expect current quarter sales to grow by 80.20% and then jump by 41.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -67.06%. While earnings are projected to return 3.44% in 2024.
VERV Dividends
Verve Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Verve Therapeutics Inc insiders own 7.65% of total outstanding shares while institutional holders control 88.06%, with the float percentage being 95.35%. Alphabet Inc. is the largest shareholder of the company, while 239 institutions own stock in it. As of Jun 29, 2023, the company held over 10.55 million shares (or 16.56% of all shares), a total value of $197.8 million in shares.
The next largest institutional holding, with 6.05 million shares, is of FMR, LLC’s that is approximately 9.49% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $113.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of Verve Therapeutics Inc (VERV) shares are ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF. Data provided on Sep 29, 2023 indicates that ARK ETF Tr-ARK Genomic Revolution ETF owns about 2.84 million shares. This amounts to just over 4.46 percent of the company’s overall shares, with a $37.69 million market value. The same data shows that the other fund manager holds slightly less at 2.12 million, or about 3.33% of the stock, which is worth about $28.1 million.
